RaQualia Pharma Inc.
4579.T · JPX
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | ¥3 | ¥2 | ¥3 | ¥3 |
| % Growth | 63.5% | -34.8% | 5.1% | – |
| Cost of Goods Sold | ¥1 | ¥0 | ¥0 | ¥0 |
| Gross Profit | ¥2 | ¥2 | ¥3 | ¥2 |
| % Margin | 79.9% | 87.1% | 92.1% | 88.4% |
| R&D Expenses | ¥2 | ¥1 | ¥1 | ¥1 |
| G&A Expenses | ¥1 | ¥1 | ¥1 | ¥1 |
| SG&A Expenses | ¥1 | ¥1 | ¥1 | ¥1 |
| Sales & Mktg Exp. | ¥0 | ¥0 | ¥0 | ¥0 |
| Other Operating Expenses | ¥0 | ¥0 | ¥0 | ¥0 |
| Operating Expenses | ¥3 | ¥2 | ¥2 | ¥2 |
| Operating Income | -¥0 | -¥0 | ¥1 | ¥1 |
| % Margin | -6.9% | -17.7% | 29.7% | 25.5% |
| Other Income/Exp. Net | -¥0 | ¥0 | -¥0 | ¥0 |
| Pre-Tax Income | -¥0 | -¥0 | ¥1 | ¥1 |
| Tax Expense | ¥0 | ¥0 | ¥0 | ¥0 |
| Net Income | -¥0 | -¥0 | ¥1 | ¥1 |
| % Margin | -15.9% | -17% | 24.8% | 27.2% |
| EPS | -22.87 | -14.98 | 34.5 | 36.07 |
| % Growth | -52.7% | -143.4% | -4.4% | – |
| EPS Diluted | -22.87 | -14.98 | 34.47 | 36.04 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | ¥0 | ¥0 | ¥0 | ¥0 |
| Interest Expense | ¥0 | ¥0 | ¥0 | ¥0 |
| Depreciation & Amortization | ¥0 | ¥0 | ¥0 | ¥0 |
| EBITDA | ¥0 | -¥0 | ¥1 | ¥1 |
| % Margin | 6.1% | -5.9% | 34.4% | 36.9% |